Jupiter Life Line Hospitals Limited — Q3 FY26 earnings call

Call held 2 Feb 2026

Management summary

Jupiter Life Line Hospitals reported robust revenue and EBITDA growth for Q3 and 9M FY26, highlighted by the early and on-budget completion of its 500-bed Dombivli hospital. While profitability was affected by a one-time Labor Code provision, the company anticipates an EBITDA drag and higher depreciation from the new facility for the next two years. Operational metrics like ARPOB showed strong improvement, and the company continues its expansion plans in Western India.

Highlights

  • Dombivli hospital completed ahead of schedule and within budget at INR 425 crores capex, commencing operations with 200 beds in Phase 1.

  • Q3 FY26 Total income increased 9.8% YoY to INR 365.3 crores, driven primarily by ARPOB growth.

  • Q3 FY26 EBITDA grew 9.2% YoY to INR 83.4 crores, maintaining a healthy margin of 22.8%.

  • 9M FY26 Total income and EBITDA showed strong growth of 15.1% and 15.2% YoY respectively.

  • Indore hospital's ARPOB is expected to grow faster than inflation for the next couple of years, indicating strong performance in its growth phase.

Concerns

  • Q3 FY26 PAT decreased 18.7% YoY to INR 42.5 crores, impacted by a one-time INR 6.4 crores provision for the new Labor Code.

  • The new Dombivli hospital is expected to cause an EBITDA drag on consolidated numbers for the next 2 years.

  • A significantly higher depreciation load is anticipated starting next quarter due to the Dombivli hospital.

Key financials

2 periods

Q3 FY26

  • Total Income
    ₹365.3 Cr
    YoY +9.8%
  • EBITDA
    ₹83.4 Cr
    YoY +9.2%
  • EBITDA Margin
    22.8%
  • PAT
    ₹42.5 Cr
    YoY -18.7%
  • PAT Margin
    11.6%
  • ARPOB
    ₹68,000
  • Occupancy
    61.4%

9M FY26

  • Total Income
    ₹1,111.9 Cr
    YoY +15.1%
  • EBITDA
    ₹254 Cr
    YoY +15.2%
  • EBITDA Margin
    22.8%
  • PAT
    ₹143.9 Cr
    YoY -3.1%
  • PAT Margin
    12.9%
  • ARPOB
    ₹66,800
  • ALOS
    3.85 days
  • Average Occupancy
    61.9%

What they filed

Q1 FY27: revenue up 16.4%, net profit down 13.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue335 333 337 353 394 +18%365 +10%388 +15%411 +16%
EBITDA78 76 80 78 92 +18%83 +9%89 +11%79 +1%
Net profit52 52 45 44 57 +10%42 −19%50 +11%38 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex Capex disclosed
    • Dombivli hospital project (total) ₹425 Cr
    • Pune Bibvewadi project (so far) ₹45 Cr
    The 750,000 square foot 500-bed structure has been completed before time and on budget, ahead of its planned launch in Q1 of FY '27. This was a phenomenal project execution effort wherein we were able to complete the entire construction for the 500-bed, fit-outs for over 300 beds and all biomedical equipment installation in just over 24 months and at a capex of roughly INR425 crores. So, Dombivli, as I said, INR425 crores is the total that we have spent for the project. Pune, I can see a number of around INR45 crores so far.

Guidance & targets

Profitability

  • Dombivli Hospital EBITDA Breakeven Profitability · by end of year 2 · High confidence Breakeven
    By end of year 2, we expect to be EBITDA breakeven.

    — Ankit Thakker

  • Dombivli Hospital EBITDA Drag Profitability · first year · High confidence INR 2-3 crores a month
    In the past, as I have said, our previous hospital experience is first year, something between INR 2 crores to INR 3 crores a month should be the average for the first year.

    — Ankit Thakker

  • Consolidated EBITDA Margin Drag Profitability · next 2 years · High confidence drag
    should also expect an EBITDA drag on the consolidated numbers for around the next 2 years before the new hospital can start contributing financially.

    — Ankit Thakker

Capex

  • Pune Bibvewadi Project Completion Capex · calendar year '28 · High confidence Calendar year '28
    As we have said, we are slated to begin sometime in calendar year '28, and we are reasonably sure to achieve that target.

    — Ankit Thakker

Margin

  • Indore ARPOB Growth Margin · next couple of years · High confidence faster than inflation
    Indore ARPOB for the next couple of years should grow a little faster than inflation logically, and that is what we are also seeing play out.

    — Ankit Thakker

  • Thane/Pune ARPOB Growth Margin · ongoing · High confidence inflation-linked
    Thane Pune will be inflation-linked growth.

    — Ankit Thakker

  • Mature Hospitals ARPOB Growth Margin · ongoing · High confidence in line with inflation
    After which, it only grows in line with inflation. So that would be my broad guidance to you that the mature asset ARPOBS should grow in line with inflation and the newer hospitals should grow a little faster in the earlier phases. And once they mature, they should grow in line with inflation.

    — Ankit Thakker

What to watch in Q4 FY26

Dombivli Hospital Operational Ramp-up

Next quarter (Q4 FY26 results)
Current Inaugurated Feb 15, 200 beds in Phase 1
Target Initial occupancy rates and revenue contribution

Why it matters

This is the first quarter of operations for the new 500-bed facility, and its initial performance will indicate the pace of ramp-up and the start of the expected EBITDA drag.

The hospital is slated to be inaugurated on February 15 and will commence full clinical operations thereafter. In the interest of operational efficiency, we will only begin operating 200 beds in Phase 1 and then ramp up capacity in a phased manner as the occupancy increases.

Risks & concerns

  • EBITDA drag from new Dombivli hospital

    high

    Dombivli hospital expected to cause an EBITDA drag on consolidated numbers for the next 2 years, averaging INR 2-3 crores per month in the first year.

    Management acknowledged

  • Higher depreciation load from new hospital

    medium

    A much higher depreciation load is expected on the consolidated numbers starting next quarter due to the Dombivli hospital.

    Management acknowledged

  • Nurse availability as a national challenge

    medium

    Management stated that nurse availability is a national challenge, though not specific to Jupiter or its locations.

    Management acknowledged

  • Uncertainty of long-term macroeconomic and regulatory factors on margins

    medium

    Management expressed uncertainty about the long-term impact of macroeconomics, wages, trade, capex, consumables, GST, and taxation on margins, calling it 'too much astrology'.

    Management not addressed

  • One-time provision for new Labor Code

    low

    PBT was impacted by INR 6.4 crores in Q3 FY26 due to an exceptional one-time provision related to the new Labor Code.

    Management acknowledged

Q&A highlights

7 direct
Dombivli Hospital Financial Impact (EBITDA drag and breakeven timeline) Direct
By end of year 2, we expect to be EBITDA breakeven. In the past, as I have said, our previous hospital experience is first year, something between INR 2 crores to INR 3 crores a month should be the average for the first year.

Provides specific financial expectations and timelines for the new hospital, crucial for near-term profitability forecasts.

Asked by Ashutosh Nemani

Q3 FY26 PAT Decline and Labor Code Impact Direct
Our PBT in this quarter is, therefore, impacted to the tune of INR6.4 crores due to this exceptional onetime provision.

Clarifies the primary reason for the significant YoY decline in PAT, attributing it to a one-time event rather than operational weakness.

Asked by Amit Thawani

ARPOB as the main driver for Q3 revenue growth Direct
So almost entire 10% growth this quarter is from ARPOB? Yes.

Indicates that revenue growth is primarily driven by an increase in average revenue per occupied bed, suggesting either pricing power or a favorable case mix.

Asked by Amit Thawani

Long-term ARPOB strategy and targets Direct
We do not have any ARPOB target either now or for the future. We think that this ARPOB number is more of a byproduct of what you do. Generally, in the initial phases of operations, as I was saying earlier, the ARPOBS are lower because you do more of primary and secondary work. But as the hospital matures, the ARPOB also reaches maturity. After which, it only grows in line with inflation.

Explains management's philosophy on ARPOB, stating it's an outcome of service mix and maturity rather than a direct target, with mature hospitals growing with inflation.

Asked by Kaustav Bubna

Availability of star doctors/nurses and rising doctor costs Direct
Nurses is a national challenge, and there is nothing new. On the doctor side, my view is that if you are in large cities, then you don't have too much of a problem. Doctor cost in smaller cities is much higher than doctor cost in larger cities. But in the locations that we operate, it is not hard to find good doctors. Typically, the doctor cost varies between 20% and 25% of the top line and we have generally been in that range.

Addresses a key sector-wide concern regarding talent acquisition and costs, providing reassurance that it's manageable for Jupiter in its chosen locations.

Asked by Ashutosh Nemani

Plans for a seventh hospital and long-term capex strategy Partial
We are keen to do the seventh hospital as well. We remain committed to Western India for now. We are in discussions with a few opportunities currently, but I don't have any announcement to make about where that location will be and when it will really mature because we are keen to do a greenfield and land being land with all its uncertainties in India, you can't really go out and make predictions before you deliver.

Offers insight into the company's future expansion pipeline and strategic focus on Western India, while highlighting the challenges of greenfield development.

Asked by Kaustav Bubna

Impact of new Labor Code on PBT Direct
Our PBT in this quarter is, therefore, impacted to the tune of INR6.4 crores due to this exceptional onetime provision.

Directly quantifies the financial impact of a new regulatory change on the company's profit before tax.

Asked by Ankit Thakker (self-initiated)

Benefit from CGHS price hikes Direct
So we currently don't have any CGHS exposure on our P&L. So as we stand today, it does not impact us.

Clarifies that a potential industry tailwind from government scheme revisions will not benefit Jupiter due to its minimal exposure.

Asked by Aryamaan

3 min read 6 chapters

Detailed narrative

Dombivli Hospital Launch and Financial Outlook

The new 500-bed Dombivli hospital, constructed with a capex of INR 425 crores, was completed ahead of schedule and within budget. It is slated for inauguration on February 15, 2026, and will commence full clinical operations thereafter, initially with 200 beds in Phase 1. Management anticipates an EBITDA drag of INR 2-3 crores per month for the first year and expects the hospital to achieve EBITDA breakeven by the end of its second year of operation. A significantly higher depreciation load on consolidated numbers is also expected starting next quarter.

Q3 and 9M FY26 Financial Performance Overview

For Q3 FY26, Jupiter Life Line Hospitals reported a total income of INR 365.3 crores, marking a 9.8% YoY increase, with EBITDA growing 9.2% YoY to INR 83.4 crores, resulting in a 22.8% margin. However, PAT decreased 18.7% YoY to INR 42.5 crores, primarily due to a one-time provision of INR 6.4 crores related to the new Labor Code. For the nine months ended December 31, 2025, total income rose 15.1% YoY to INR 1,111.9 crores, and EBITDA increased 15.2% YoY to INR 254 crores (22.8% margin), while PAT saw a modest decline of 3.1% YoY to INR 143.9 crores.

Operational Metrics and ARPOB Growth Drivers

The company's ARPOB for Q3 FY26 stood at 68,000, representing an approximate 15% growth from the previous year's 59,000+. The 9-month ARPOB was 66,800, with an average length of stay (ALOS) of 3.85 days and an average occupancy rate of 61.9%. Management confirmed that the majority of the 10% revenue growth in Q3 was driven by ARPOB improvement, indicating a favorable case mix or pricing power. For mature hospitals, ARPOB is expected to grow in line with inflation, while newer facilities like Indore are projected to see faster-than-inflation growth for the next couple of years.

Expansion Projects and Future Capex Plans

Beyond the Dombivli project, the Pune Bibvewadi project has commenced basement construction, with an incurred capex of INR 45 crores to date, targeting completion by calendar year 2028. The Mira Road project is currently undergoing regulatory approval. The company remains committed to its long-term strategy of expanding in large cities across Western India, focusing on micro-markets with high resident populations and underserved tertiary care needs. Discussions are ongoing for a potential seventh hospital, reinforcing the company's growth ambitions.

Talent Acquisition and Retention Strategy

Addressing concerns about the availability of medical professionals, management acknowledged nurse availability as a national challenge but stated that attracting good doctors is not an issue in their large city locations. Doctor costs typically range between 20-25% of the top line, and Jupiter maintains a mix of exclusive and visiting practitioners to ensure comprehensive care delivery. The company reported minimal doctor attrition, with only one full-time doctor moving, indicating stable talent retention.

Payer Mix and Government Scheme Exposure

For the nine-month period, Jupiter's payer mix consisted of 55.7% from insurance, 43.2% from self-payers, and a minimal 1.1% from government schemes. Management clarified that the company has no CGHS exposure on its P&L, thus the recent CGHS price hikes will not impact Jupiter. The company participates in government schemes only for specific treatments like radiation for cancer and congenital heart diseases for children, viewing this as a social contribution with no meaningful financial impact.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls